• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

MMWR Morb Mortal Wkly Rep. Notes from the Field: Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae Producing New Delhi Metallo-Beta-Lact

Giuseppe

Emeritus
[Source: US Centers for Disease Control and Prevention, MMWR Morbidity and Mortality Weekly Report, full page: (LINK). Edited.]

Notes from the Field: Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae Producing New Delhi Metallo-Beta-Lactamase ? Denver, Colorado, 2012

Weekly

February 15, 2013 / 62(06);108-108



On August 16, 2012, the Colorado Department of Public Health and Environment was notified of two patients at an acute-care hospital in Denver with carbapenem-resistant Enterobacteriaceae (CRE), specifically Klebsiella pneumoniae (CRKP), isolated from respiratory specimens during July?August. Both isolates produced New Delhi metallo-beta-lactamase (NDM). A review of microbiology records identified a third patient with NDM-producing CRKP isolated from a respiratory specimen, admitted in May. Active surveillance cultures in September identified an additional five patients colonized with NDM-producing CRKP. An investigation was launched by the hospital and the Colorado Department of Public Health and Environment to guide infection control measures and limit transmission.



A case was defined as NDM-producing CRE isolated from clinical or active surveillance cultures collected from a patient while hospitalized during January 1?October 30, 2012. Medical records were reviewed for clinical and epidemiologic characteristics. Relatedness of isolates was evaluated by pulsed-field gel electrophoresis (PFGE).

The eight patients were aged 23?75 years and had been hospitalized at one or more of 11 different units in the hospital for a median of 18 days (range: 12?83 days) before CRKP identification. Three were treated for CRKP infection, and five were found to be asymptomatically colonized; none died.

Initial isolates were resistant to all antimicrobials except tigecycline, to which all were susceptible. Colistin minimum inhibitory concentrations for six isolates were low (≤2 ?g/mL), suggesting this agent might be a treatment option. All isolates were highly related by PFGE. Epidemiologic tracing to determine temporal overlap of patients on units in the hospital indicated multiple transmission events had occurred, and three units were likely transmission sites. Acquisition of NDM-producing CRE by some patients was not explained by direct overlap and suggested that undetected, asymptomatically colonized patients were involved in some transmission routes.

How NDM-producing CRE was introduced to the facility is unclear.

NDM, a carbapenemase enzyme first described in 2009 in a patient who had received medical care in India (1), has since been detected and reported worldwide (2). In the United States, before this outbreak, only 16 isolates in clusters with two or fewer cases had been identified since 2009; 14 isolates were from patients who had received medical care in endemic (South Asian) regions. The cases described here represent the largest U.S. outbreak of NDM-producing CRE to date, highlighting the risk for spread of these organisms among persons receiving medical care inside the United States.

Evidence that undetected, asymptomatically colonized patients likely contributed to the size of the outbreak highlights the importance of timely active surveillance cultures when CRE is identified to direct infection control measures and limit further transmission (3).



Reported by

Larissa Pisney, MD, Michelle Barron MD, Div of Infectious Diseases, Univ of Colorado; Sarah Jackson Janelle, MPH, Wendy Bamberg, MD, Colorado Dept of Public Health and Environment. Duncan MacCannell, PhD, Antimicrobial Resistance and Characterization Laboratory; Alexander Kallen, MD, Carolyn Gould, MD, Brandi Limbago, PhD, Div of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases; Erin Epson, MD, Joyanna Wendt, MD, EIS officers, CDC. Corresponding contributor: Erin Epson, erin.epson@state.co.us, 303-692-2745.



References
  1. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009;53:5046?54.
  2. Wilson ME, Chen LH. NDM-1 and the role of travel in its dissemination. Curr Infect Dis Rep 2012;14:213?26.
  3. CDC. 2012 CRE toolkit: guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). Atlanta, GA: US Department of Health and Human Services, CDC; 2012. Available at http://www.cdc.gov/hai/organisms/cre/cre-toolkit.
-
------
 
Back
Top Bottom